SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients ...
Fifteen former standouts in the National Football League have reached the doorstep of enshrinement into the Pro Football Hall ...
Hosted on MSN
Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors
Erasca Inc. (NASDAQ:ERAS) is one of the stocks under $10 to buy now. Earlier on June 2, Erasca announced that the US FDA had cleared its Investigational New Drug/IND application for ERAS-4001. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback